< -5%

-5% to -3%

Guj Mineral

Coal India

-3% to 0%

0% to 3%

3% to 5%

Nifty Bank index recovered over 300 points, briefly crossing the 59,000 mark, Axis Bank and Canara Bank led gains; ICICI and HDFC Bank traded in the red, Analysts expect consolidation between 58,500–60,100; caution advised

* Nifty Bank index recovered over 300 points, briefly crossing the 59,000 mark
* Axis Bank and Canara Bank led gains; ICICI and HDFC Bank traded in the red
* Analysts expect consolidation between 58,500–60,100; caution advised

Nifty Bank index rebounded over 300 points, briefly crossing 59,000, led by Axis Bank and Canara Bank gains. Analysts expect consolidation between 58,500–60,100, with key resistance at 59,200–59,500 and support at 58,500–58,700.

shorts/business/bank-nifty-recovers-300-pts-from-day-s-low-to-cross-59-000-check-key-levels-to-watch-out-for

* Nifty Bank index recovered over 300 points, briefly crossing the 59,000 mark
* Axis Bank and Canara Bank led gains; ICICI and HDFC Bank traded in the red
* Analysts expect consolidation between 58,500–60,100; caution advised

Bank stocks recorded a sharp recovery in the morning to push the <a href="https://www.moneycontrol.com/indian-indices/NIFTY-BANK-23.html">Nifty Bank index</a>  into the green briefly after a four-session losing streak. The index crossed the 59,000-mark, with shares of Axis Bank and Canara Bank leading gains.

After hitting a day's low at 58,737.60, the Nifty Bank index recovered more than 300 points to hit a day’s high at 59,076.10. Check key technical levels to watch out for some upside chances or more downside.
<h3><strong>Technical view on Bank Nifty:</strong></h3>
Despite the recovery, analysts advise caution. Going ahead, the index is expected to remain in a consolidation phase and build a base within the 58,500–60,100 range over the coming weeks, said Bajaj Broking.

It added that a decisive move above the last two weeks' high of 59,500 could pave the way for a fresh upside toward the recent all-time high near 60,100 in the weeks ahead. "The sharp rally over the past two months remains well-contained within an upward price channel, highlighting sustained demand even at higher levels. On the downside, strong support is placed in the 58,300–58,600 zone, which coincides with the 50-day EMA and the previous breakout region. Holding above this support band would keep the broader trend constructive,” it said.

Choice Broking meanwhile said that the banking index will find immediate resistance at 59,150–59,250, while supports at 58,600 and 58,700 remain critical for preserving near-term stability in the index.

From a technical standpoint, the index remains sandwiched between key reference zones, said SAMCO Securities. "While it is trading below the middle Bollinger Band near 59,200, it continues to defend the 50-day simple moving average placed around 58,700. This narrow compression in price action suggests muted volatility, with the index neither showing signs of a meaningful breakdown nor offering clarity on a sustainable upside move at this juncture," it added.

The domestic brokerage said that the index will find immediate resistance near 59,100, followed by 59,200 on the upside. "A stronger supply zone is visible around 59,350, which has previously acted as a rejection area and remains a key hurdle for any meaningful recovery," it added.

Angel One expects Bank Nifty to find key support at 58,800 -58,500 on the downside, and resistance at 59,300 -59,500 on the upside.
<h3><strong>Top losers on the Nifty Bank index today:</strong></h3>
<a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/axisbank/AB16">Axis Bank</a> shares were the top gainers of the index, rising nearly 1 percent. <a href="https://www.moneycontrol.com/india/stockpricequote/banks-public-sector/canarabank/CB06">Canara Bank</a> and Federal Bank shares also gained around 1 percent each.

AU Small Finance Bank, State Bank of India (<a href="https://www.moneycontrol.com/india/stockpricequote/banks-public-sector/statebankindia/SBI">SBI</a>), Bank of Baroda, Punjab National Bank (<a href="https://www.moneycontrol.com/india/stockpricequote/banks-public-sector/punjabnationalbank/PNB05">PNB</a>) and IDFC First Bank shares were trading in the green with marginal gains. Bucking the trend, ICICI Bank, <a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/hdfcbank/HDF01">HDFC Bank</a>, IndusInd Bank and Kotak Mahindra Bank shares were trading in the red.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-flat-start-us-asian-markets-fall-3-liveblog-13747857.html">LIVE updates</a> from the stock markets here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Bank Nifty recovers 300 pts from day's low to cross 59,000: Check key levels to watch out for

Bank stocks recorded a sharp recovery in the morning to push the Nifty Bank index  into the green briefly after a four-session losing streak. The index crossed the 59,000-mark, with shares of Axis Bank and Canara Bank leading gains.

After hitting a day's low at 58,737.60, the Nifty Bank index recovered more than 300 points to hit a day’s high at 59,076.10. Check key technical levels to watch out for some upside chances or more downside.
Technical view on Bank Nifty:
Despite the recovery, analysts advise caution. Going ahead, the index is expected to remain in a consolidation phase and build a base within the 58,500–60,100 range over the coming weeks, said Bajaj Broking.

It added that a decisive move above the last two weeks' high of 59,500 could pave the way for a fresh upside toward the recent all-time high near 60,100 in the weeks ahead. &quot;The sharp rally over the past two months remains well-contained within an upward price channel, highlighting sustained demand even at higher levels. On the downside, strong support is placed in the 58,300–58,600 zone, which coincides with the 50-day EMA and the previous breakout region. Holding above this support band would keep the broader trend constructive,” it said.

Choice Broking meanwhile said that the banking index will find immediate resistance at 59,150–59,250, while supports at 58,600 and 58,700 remain critical for preserving near-term stability in the index.

From a technical standpoint, the index remains sandwiched between key reference zones, said SAMCO Securities. &quot;While it is trading below the middle Bollinger Band near 59,200, it continues to defend the 50-day simple moving average placed around 58,700. This narrow compression in price action suggests muted volatility, with the index neither showing signs of a meaningful breakdown nor offering clarity on a sustainable upside move at this juncture,&quot; it added.

The domestic brokerage said that the index will find immediate resistance near 59,100, followed by 59,200 on the upside. &quot;A stronger supply zone is visible around 59,350, which has previously acted as a rejection area and remains a key hurdle for any meaningful recovery,&quot; it added.

Angel One expects Bank Nifty to find key support at 58,800 -58,500 on the downside, and resistance at 59,300 -59,500 on the upside.
Top losers on the Nifty Bank index today:
Axis Bank shares were the top gainers of the index, rising nearly 1 percent. Canara Bank and Federal Bank shares also gained around 1 percent each.

AU Small Finance Bank, State Bank of India (SBI), Bank of Baroda, Punjab National Bank (PNB) and IDFC First Bank shares were trading in the green with marginal gains. Bucking the trend, ICICI Bank, HDFC Bank, IndusInd Bank and Kotak Mahindra Bank shares were trading in the red.

Follow all LIVE updates from the stock markets here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Orient Tech shares rose 13% after 1:10 bonus issue approval., Shareholders approved the bonus issue, boosting investor confidence, Record date for bonus share eligibility is yet to be announced

* Orient Tech shares rose 13% after 1:10 bonus issue approval.
* Shareholders approved the bonus issue, boosting investor confidence
* Record date for bonus share eligibility is yet to be announced

Orient Technologies shares surged over 13% after shareholders approved a 1:10 bonus issue, reflecting confidence in the company’s financial strength and growth strategy. The record date for eligibility is yet to be announced.

shorts/business/orient-tech-shares-jump-13-on-1-10-bonus-issue-announcement-what-it-means-for-shareholders

* Orient Tech shares rose 13% after 1:10 bonus issue approval.
* Shareholders approved the bonus issue, boosting investor confidence
* Record date for bonus share eligibility is yet to be announced

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/software/orienttechnologies/OTL">Orient Technologies</a> jumped more than 13 percent on December 29 after the company announced that its shareholders have considered and approved a bonus issue of shares in the ratio of 1:10.

The shares of the Mumbai-based IT solutions-provider rose to Rs 373.95 apiece in the morning trading hours of Tuesday, the highest level seen by the stock in more than a month.
<h3><strong>Orient Tech bonus issue:</strong></h3>
Earlier in November, Orient Tech had announced that its board of directors have considered and approved the plan to issue bonus shares in the ratio of 1:10 to its eligible shareholders.

In an exchange filing released on Monday, the company announced that its shareholders too have approved the plan, marking an “important milestone” in its ongoing journey of “sustainable value creation”.

“The approval, received through a Postal Ballot process with strong shareholder participation, reflects continued investor confidence in Orient’s financial discipline, resilient operating model, and its strategic positioning in high-growth technology segments that are driving enterprise transformation across India,” it added.

As part of the corporate action, Orient Tech will implement the bonus issue through the capitalization of Rs 4.16 crore from the Securities Premium Account. The record date to determine the eligibility of the shareholders set to receive the payment is yet to be announced.
<h3><strong>What it means for shareholders?</strong></h3>
A company announces bonus issue of shares to reward its existing shareholders with an investment opportunity, which is perceived to be attractive. While the issue of bonus shares increases the total number of shares issued and owned, it does not change the market capitalization of the company. This increases the overall liquidity of the stock, and makes it more affordable for other investors to add to their portfolio, creating strong upside potential for the stock.

The issuance of bonus shares will likely increase investors' confidence for the stock, as it reflects on the firm's strong financials and growth potential. Bonus issue essentially are free shares offered by a company from its reserves. Investors must own shares of the company as on the record date to be eligible for the bonus issue.
<h3><strong>'Bonus issue reflects balance sheet strength, execution consistency'</strong></h3>
The approval of the bonus issue is a clear endorsement of the confidence shareholders have in Orient Technologies’ fundamentals, governance standards, and long-term vision, said the company’s CMD Ajay Sawant. “It reflects the strength of our balance sheet and the consistency of our execution, even as we continue to invest in future ready capabilities across cloud, cybersecurity, and managed services. Our focus remains on building a scalable, resilient, and differentiated technology services platform that delivers sustainable value to all stakeholders over the long term,” he added.

The company said that the bonus issue is not merely a capital action but a reflection of its “balance sheet, consistent performance, and prudent capital management approach”. It noted that it has maintained a disciplined focus on strengthening its financial position while continuing to invest in core growth areas such as cloud services, cybersecurity, managed services, and digital transformation over the years.
<h3><strong>Orient Tech share price:</strong></h3>
Orient Tech shares have gained nearly 10 percent in the past five days, and around 4 percent in the past one month. The stock jumped around 6 percent in the past six months, but is down around 24 percent in 2025 so far.

Its P/E ratio currently stands at around 27.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-flat-start-us-asian-markets-fall-3-liveblog-13747857.html">LIVE updates</a> from the stock markets here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Orient Tech shares jump 13% on 1:10 bonus issue announcement: What it means for shareholders

The shares of Orient Technologies jumped more than 13 percent on December 29 after the company announced that its shareholders have considered and approved a bonus issue of shares in the ratio of 1:10.

The shares of the Mumbai-based IT solutions-provider rose to Rs 373.95 apiece in the morning trading hours of Tuesday, the highest level seen by the stock in more than a month.
Orient Tech bonus issue:
Earlier in November, Orient Tech had announced that its board of directors have considered and approved the plan to issue bonus shares in the ratio of 1:10 to its eligible shareholders.

In an exchange filing released on Monday, the company announced that its shareholders too have approved the plan, marking an “important milestone” in its ongoing journey of “sustainable value creation”.

“The approval, received through a Postal Ballot process with strong shareholder participation, reflects continued investor confidence in Orient’s financial discipline, resilient operating model, and its strategic positioning in high-growth technology segments that are driving enterprise transformation across India,” it added.

As part of the corporate action, Orient Tech will implement the bonus issue through the capitalization of Rs 4.16 crore from the Securities Premium Account. The record date to determine the eligibility of the shareholders set to receive the payment is yet to be announced.
What it means for shareholders?
A company announces bonus issue of shares to reward its existing shareholders with an investment opportunity, which is perceived to be attractive. While the issue of bonus shares increases the total number of shares issued and owned, it does not change the market capitalization of the company. This increases the overall liquidity of the stock, and makes it more affordable for other investors to add to their portfolio, creating strong upside potential for the stock.

The issuance of bonus shares will likely increase investors' confidence for the stock, as it reflects on the firm's strong financials and growth potential. Bonus issue essentially are free shares offered by a company from its reserves. Investors must own shares of the company as on the record date to be eligible for the bonus issue.
'Bonus issue reflects balance sheet strength, execution consistency'
The approval of the bonus issue is a clear endorsement of the confidence shareholders have in Orient Technologies’ fundamentals, governance standards, and long-term vision, said the company’s CMD Ajay Sawant. “It reflects the strength of our balance sheet and the consistency of our execution, even as we continue to invest in future ready capabilities across cloud, cybersecurity, and managed services. Our focus remains on building a scalable, resilient, and differentiated technology services platform that delivers sustainable value to all stakeholders over the long term,” he added.

The company said that the bonus issue is not merely a capital action but a reflection of its “balance sheet, consistent performance, and prudent capital management approach”. It noted that it has maintained a disciplined focus on strengthening its financial position while continuing to invest in core growth areas such as cloud services, cybersecurity, managed services, and digital transformation over the years.
Orient Tech share price:
Orient Tech shares have gained nearly 10 percent in the past five days, and around 4 percent in the past one month. The stock jumped around 6 percent in the past six months, but is down around 24 percent in 2025 so far.

Its P/E ratio currently stands at around 27.

Follow all LIVE updates from the stock markets here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

UGC NET December 2025 admit cards released for January 2, 2026 exam, Admit cards available for download at ugcnet.nta.nic.in, Candidates must carry admit card, photo ID, and photo on exam day

* UGC NET December 2025 admit cards released for January 2, 2026 exam
* Admit cards available for download at ugcnet.nta.nic.in
* Candidates must carry admit card, photo ID, and photo on exam day

NTA has released UGC NET December 2025 admit cards for candidates with exams on January 2, 2026. Aspirants can download their hall tickets from ugcnet.nta.nic.in and must bring the admit card, valid photo ID, and a passport photo to the exam center.

shorts/education/ugc-net-admit-card-2025-out-for-january-2-exam-ugcnet-nta-nic-in-direct-link-here

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/refineries/sundrexoilcompany/SOCL">Sundrex Oil Company</a> made a weak market debut on stock markets on December 30, listing at Rs 68.80 apiece on the NSE Emerge platform. This marks a discount of 20 percent over the SME IPO price of Rs 86 apiece.

The company debuted with a market capitalization of Rs 92.15 crore.
<h3><strong>Sundrex Oil Company IPO GMP:</strong></h3>
Ahead of listing, the unlisted shares of Sundrex Oil Company were trading flat at the IPO price with zero grey market premium (GMP) at Rs 86 apiece, according to data on Investorgain. The GMP had sharply declined from the 19.77 percent quoted a day before the IPO opened for public bidding.

According to IPO Watch too, the unlisted shares of the company were trading with zero GMP over the <a href="https://www.moneycontrol.com/ipo/sundrex-oil-company-ltd-socl-ipodetail">IPO price</a>.
<h3><strong>About Sundrex Oil Company IPO:</strong></h3>
Sundrex Oil Company launched its IPO earlier this month to raise Rs 32 crore entirely through a fresh issue of shares at a price band of Rs 81-86 per share. Investors could bid for a minimum of 3,200 shares, requiring an investment of 2.75 lakh at the upper price band, and in multiples of 1,600 thereafter.

The maiden public issue of the manufacturer and wholesaler of lubricants, greases, and a wide range of industrial products, was fully subscribed during its three days of public bidding between December 22 and December 24. Retail investors showed the most interest in the IPO, booking their reserved portion nearly 2 times.

The company aims to use the fresh issue proceeds to meet the working capital requirements and capital expenditure, as well as prepayment and repayment of all or a portion of certain secured and unsecured loans, general corporate purpose and to meet the offer expenses.

Follow all <a href="https://www.moneycontrol.com/ipo/">IPO news</a> here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Weak market debut: Sundrex Oil Company shares list at 20% discount to SME IPO price

The shares of Sundrex Oil Company made a weak market debut on stock markets on December 30, listing at Rs 68.80 apiece on the NSE Emerge platform. This marks a discount of 20 percent over the SME IPO price of Rs 86 apiece.

The company debuted with a market capitalization of Rs 92.15 crore.
Sundrex Oil Company IPO GMP:
Ahead of listing, the unlisted shares of Sundrex Oil Company were trading flat at the IPO price with zero grey market premium (GMP) at Rs 86 apiece, according to data on Investorgain. The GMP had sharply declined from the 19.77 percent quoted a day before the IPO opened for public bidding.

According to IPO Watch too, the unlisted shares of the company were trading with zero GMP over the IPO price.
About Sundrex Oil Company IPO:
Sundrex Oil Company launched its IPO earlier this month to raise Rs 32 crore entirely through a fresh issue of shares at a price band of Rs 81-86 per share. Investors could bid for a minimum of 3,200 shares, requiring an investment of 2.75 lakh at the upper price band, and in multiples of 1,600 thereafter.

The maiden public issue of the manufacturer and wholesaler of lubricants, greases, and a wide range of industrial products, was fully subscribed during its three days of public bidding between December 22 and December 24. Retail investors showed the most interest in the IPO, booking their reserved portion nearly 2 times.

The company aims to use the fresh issue proceeds to meet the working capital requirements and capital expenditure, as well as prepayment and repayment of all or a portion of certain secured and unsecured loans, general corporate purpose and to meet the offer expenses.

Follow all IPO news here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/consumer-food/shyamdhaniindustries/SDI01">Shyam Dhani Industries</a> made a bumper debut on stock markets on December 30, listing at Rs 133 apiece on the NSE Emerge platform. This marks a 90 percent premium over the SME IPO price of Rs 70 per share.

The company debuted with a market capitalisation of Rs 282 crore.
<h3><strong>Shyam Dhani Industries IPO GMP:</strong></h3>
The listing premium is more or less at par with the strong grey market estimates. Ahead of listing, the unlisted shares of the company were trading with more than 97 percent grey market premium (GMP) over the <a href="https://www.moneycontrol.com/ipo/shyam-dhani-industries-sdi01-ipodetail">IPO price</a>, according to data on Investorgain.

The GMP quoted by the site has slightly fallen from the 100 percent quoted two days back.
<h3><strong>Shyam Dhani Industries IPO:</strong></h3>
Spices maker Shyam Dhani Industries had launched its IPO earlier this month to raise Rs 38.48 crore from the primary markets through a fresh issue of 55 lakh shares and no offer for sale (OFS) component. This means that the entire IPO proceeds will go to the company.

The maiden public issue of the company saw <a href="https://www.moneycontrol.com/news/business/ipo/shyam-dhani-ipo-closes-with-over-918x-subscription-gmp-rises-to-100-ahead-of-listing-13742086.html">strong investor interest</a> during its three days of public bidding, being subscribed 918 times between December 22 and December 24. The price band for the IPO was set at Rs 65-70 per share.

Retail investors could bid for a minimum of 2,000 shares, requiring an investment of Rs 2.6 lakh, and in multiples thereafter. Demand remained robust across all investor categories, with non-institutional investors (NIIs) and retail investors subscribing their reserved portions 1,613 times and 1,138 times respectively. The portion reserved for qualified institutional buyers (QIB) was subscribed 256.2 times.
<h3><strong>How will the IPO proceeds be used?</strong></h3>
The IPO proceeds will be used for working capital requirements, brand creation and marketing expenses, the purchase of new machinery to be installed at the existing manufacturing unit, and the purchase and installation of a solar rooftop plant.

Additionally, the company will use a portion of the IPO funds to reduce certain debts, while the remaining amount will be deployed for general corporate purposes.

Follow all <a href="https://www.moneycontrol.com/ipo/">IPO news</a> here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Bumper market debut: Shyam Dhani Industries shares list at 90% premium to SME IPO price

The shares of Shyam Dhani Industries made a bumper debut on stock markets on December 30, listing at Rs 133 apiece on the NSE Emerge platform. This marks a 90 percent premium over the SME IPO price of Rs 70 per share.

The company debuted with a market capitalisation of Rs 282 crore.
Shyam Dhani Industries IPO GMP:
The listing premium is more or less at par with the strong grey market estimates. Ahead of listing, the unlisted shares of the company were trading with more than 97 percent grey market premium (GMP) over the IPO price, according to data on Investorgain.

The GMP quoted by the site has slightly fallen from the 100 percent quoted two days back.
Shyam Dhani Industries IPO:
Spices maker Shyam Dhani Industries had launched its IPO earlier this month to raise Rs 38.48 crore from the primary markets through a fresh issue of 55 lakh shares and no offer for sale (OFS) component. This means that the entire IPO proceeds will go to the company.

The maiden public issue of the company saw strong investor interest during its three days of public bidding, being subscribed 918 times between December 22 and December 24. The price band for the IPO was set at Rs 65-70 per share.

Retail investors could bid for a minimum of 2,000 shares, requiring an investment of Rs 2.6 lakh, and in multiples thereafter. Demand remained robust across all investor categories, with non-institutional investors (NIIs) and retail investors subscribing their reserved portions 1,613 times and 1,138 times respectively. The portion reserved for qualified institutional buyers (QIB) was subscribed 256.2 times.
How will the IPO proceeds be used?
The IPO proceeds will be used for working capital requirements, brand creation and marketing expenses, the purchase of new machinery to be installed at the existing manufacturing unit, and the purchase and installation of a solar rooftop plant.

Additionally, the company will use a portion of the IPO funds to reduce certain debts, while the remaining amount will be deployed for general corporate purposes.

Follow all IPO news here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Intermittent fasting and OMAD diets remained popular for weight loss in 2025, DASH and anti-processed food diets rise for heart health and mindful eating, High-protein diets were favored for muscle building and satiety

* Intermittent fasting and OMAD diets remained popular for weight loss in 2025
* DASH and anti-processed food diets rise for heart health and mindful eating
* High-protein diets were favored for muscle building and satiety

Top 2025 diet trends include intermittent fasting, OMAD, DASH, high-protein diets, and anti-processed food diets. These focus on weight loss, improved metabolism, heart health, and mindful eating, but may not suit everyone and require medical advice.

shorts/health-and-fitness/from-omad-to-dash-these-were-the-5-most-popular-diets-of-2025

Sun Pharmaceutical Industries Ltd, the country’s largest drugmaker by revenue and market value, has slipped behind the Sensex and Nifty in 2025 — its first spell of underperformance in six years. The weakness reflects softer momentum in the US business, rising competition in generics, sustained pricing pressure at home and abroad, unfavorable currency movements across several emerging markets and continuing tariff uncertainty.

So far this year, the stock has declined about 8 percent even as both benchmark indices have risen close to 9 percent, Bloomberg data show. The broader pharma pack has also seen volatility, with Piramal Pharma down 35 percent, Mankind Pharma lower by 25 percent, Ipca Labs falling 15 percent, Lupin 11 percent, Aurobindo Pharma 8 percent and Dr Reddy’s Laboratories down 7 percent, while the Nifty Pharma index slipped 3.5 percent.

<img class="alignnone size-full wp-image-13747941" src="https://images.moneycontrol.com/static-mcnews/2025/12/20251230022255_sun-pharma.jpg" alt="sun pharma" width="700" height="700" />

US formulations delivered modest growth as competition intensified and gRevlimid volumes stayed subdued, limiting overall progress despite gains from innovative products. Analysts expect gRevlimid to make only a minimal contribution ahead, while higher research and development spending, elevated operating costs, slower revenue growth and a heavier tax burden continue to weigh on performance.

Regulatory scrutiny remains a headwind for the generics portfolio. Plants at Halol, Mohali, Dadra and Baska are at different stages of review and are implementing Corrective and Preventive Action plans. Recently, the USFDA has classified the Baska site as “Official Action Indicated,” without disclosing the number or nature of observations.

The facility manufactures key generic products including the Albuterol Ipratropium inhalant, which generates more than $100 million annually, and Amphotericin B, with sales of about $15 million. These products contribute an estimated seven percent of US revenue excluding gRevlimid and nearly two percent of core revenue, underscoring Baska’s role in Sun Pharma’s sterile-injectables network.

For now, generics remain outside tariff coverage and the proposed 100 percent tariffs on imported innovator medicines have not yet been implemented. The company does not face incremental import duties and, with part of its manufacturing base located in the US, is positioned to reassess plans if policy changes, analysts noted.

In the domestic market, performance has been steady despite pricing pressure, with momentum expected to build through recent launches such as Cequa for dry-eye disease, Tyvalzi for ischemic stroke, Rytstat for anaemia tied to chronic kidney disease and Lyvelsa to help reduce the risk of kidney failure linked to Type-2 diabetes. Analysts expect Sun Pharma to continue gaining share in the India Pharma Market, supported by strong therapy presence and an expanded field force.

Several analysts view the recent correction in large-cap pharma stocks as a buying opportunity, arguing that earnings visibility remains intact. Sun Pharma’s one-year forward price-earnings multiple stands at 32.15 times versus its 10-year average of 28 times. The stock trades at a premium to peers such as Lupin at 21.5 times, Dr Reddy’s at 20.26 times and Cipla at 25 times. According to Bloomberg, 37 of 43 analysts have a buy rating on the stock.

Brokerage Nirmal Bang has marginally pared estimates, citing firm operating costs, ongoing investment in research and development, softer topline trends and a rising tax burden. Its research highlights longer-term supports including sustained strength in branded formulations in India, the ramp-up of specialty products in the US such as LEQSELVI and UNLOXCYT, opportunities in dermatology, ophthalmology and onco-derma, and margins supported by disciplined execution.

Sun Pharma trails Sensex, Nifty first time in six years

Sun Pharmaceutical Industries Ltd, the country’s largest drugmaker by revenue and market value, has slipped behind the Sensex and Nifty in 2025 — its first spell of underperformance in six years. The weakness reflects softer momentum in the US business, rising competition in generics, sustained pricing pressure at home and abroad, unfavorable currency movements across several emerging markets and continuing tariff uncertainty.

So far this year, the stock has declined about 8 percent even as both benchmark indices have risen close to 9 percent, Bloomberg data show. The broader pharma pack has also seen volatility, with Piramal Pharma down 35 percent, Mankind Pharma lower by 25 percent, Ipca Labs falling 15 percent, Lupin 11 percent, Aurobindo Pharma 8 percent and Dr Reddy’s Laboratories down 7 percent, while the Nifty Pharma index slipped 3.5 percent.



US formulations delivered modest growth as competition intensified and gRevlimid volumes stayed subdued, limiting overall progress despite gains from innovative products. Analysts expect gRevlimid to make only a minimal contribution ahead, while higher research and development spending, elevated operating costs, slower revenue growth and a heavier tax burden continue to weigh on performance.

Regulatory scrutiny remains a headwind for the generics portfolio. Plants at Halol, Mohali, Dadra and Baska are at different stages of review and are implementing Corrective and Preventive Action plans. Recently, the USFDA has classified the Baska site as “Official Action Indicated,” without disclosing the number or nature of observations.

The facility manufactures key generic products including the Albuterol Ipratropium inhalant, which generates more than $100 million annually, and Amphotericin B, with sales of about $15 million. These products contribute an estimated seven percent of US revenue excluding gRevlimid and nearly two percent of core revenue, underscoring Baska’s role in Sun Pharma’s sterile-injectables network.

For now, generics remain outside tariff coverage and the proposed 100 percent tariffs on imported innovator medicines have not yet been implemented. The company does not face incremental import duties and, with part of its manufacturing base located in the US, is positioned to reassess plans if policy changes, analysts noted.

In the domestic market, performance has been steady despite pricing pressure, with momentum expected to build through recent launches such as Cequa for dry-eye disease, Tyvalzi for ischemic stroke, Rytstat for anaemia tied to chronic kidney disease and Lyvelsa to help reduce the risk of kidney failure linked to Type-2 diabetes. Analysts expect Sun Pharma to continue gaining share in the India Pharma Market, supported by strong therapy presence and an expanded field force.

Several analysts view the recent correction in large-cap pharma stocks as a buying opportunity, arguing that earnings visibility remains intact. Sun Pharma’s one-year forward price-earnings multiple stands at 32.15 times versus its 10-year average of 28 times. The stock trades at a premium to peers such as Lupin at 21.5 times, Dr Reddy’s at 20.26 times and Cipla at 25 times. According to Bloomberg, 37 of 43 analysts have a buy rating on the stock.

Brokerage Nirmal Bang has marginally pared estimates, citing firm operating costs, ongoing investment in research and development, softer topline trends and a rising tax burden. Its research highlights longer-term supports including sustained strength in branded formulations in India, the ramp-up of specialty products in the US such as LEQSELVI and UNLOXCYT, opportunities in dermatology, ophthalmology and onco-derma, and margins supported by disciplined execution.

Coal Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Coal industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Bank Nifty recovers 300 pts from day's low to cross 59,000: Check key levels to watch out for

Orient Tech shares jump 13% on 1:10 bonus issue announcement: What it means for shareholders

Weak market debut: Sundrex Oil Company shares list at 20% discount to SME IPO price

Bumper market debut: Shyam Dhani Industries shares list at 90% premium to SME IPO price

Sun Pharma trails Sensex, Nifty first time in six years

Coal Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Coal industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Bank Nifty recovers 300 pts from day's low to cross 59,000: Check key levels to watch out for

Orient Tech shares jump 13% on 1:10 bonus issue announcement: What it means for shareholders

Weak market debut: Sundrex Oil Company shares list at 20% discount to SME IPO price

Bumper market debut: Shyam Dhani Industries shares list at 90% premium to SME IPO price

Sun Pharma trails Sensex, Nifty first time in six years

Coal Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Coal industry stocks.